|Videos|May 1, 2019
Impact of the PACIFIC Study Updated Analysis
Advertisement
Episodes in this series
Transcript:Nicolas Girard, MD: In the updated analysis of PACIFIC, we now have a clear view of the progression pattern during durvalumab consolidation. The first point is that we have a reduction in the risk of disease progression, and this is related to a reduction in the risk of distant metastasis. Meaning that we have a decrease in the incidence of brain metastasis and lung metastasis, and we have a global effect of durvalumab on this time to distant metastasis. And this is what we have actually in the clinic. We know that after chemoradiation, we have a higher risk of recurrence in the brain, in the lung, in the liver
Advertisement
Related to this article
An OncLive workshop covered practice-changing ROS1- and ALK-directed data in NSCLC shared at ASCO 2026 and beyond.
Lung cancer experts discuss the optimal management of CNS disease in EGFR-mutated non–small cell lung cancer.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.
The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.
Risvutatug rezetecan met the primary OS end point of the phase 3 ARTEMIS-008 trial in Chinese patients with relapsed small-cell lung cancer.
Phase 3 ELEVATE data show that adjuvant ensartinib significantly improved disease-free survival vs placebo in resected ALK-positive NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
Dr Falchi on Critical Unmet Needs and Important Next Steps in DLBCL
4
Olverembatinib Plus Blinatumomab Yields High Early-Phase CR/CRi Rates in R/R Ph+ CML and B-ALL
5